Raymond James analyst John Ransom lowered the firm’s price target on CVS Health (CVS) to $110 from $115 and keeps an Outperform rating on the shares. CVS Health’s Q4 results were in line with their preannouncement, 2023 guidance was maintained, and the company announced the acquisition of Oak Street Health (OSH), the analyst tells investors in a research note.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on CVS:
